<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006233</url>
  </required_header>
  <id_info>
    <org_study_id>1462.00</org_study_id>
    <secondary_id>FHCRC-1462.00</secondary_id>
    <secondary_id>NCI-G00-1841</secondary_id>
    <secondary_id>CDR0000068157</secondary_id>
    <nct_id>NCT00006233</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy, Total-Body Irradiation, Peripheral Stem Cell Transplantation, and Lymphocyte Infusion in Treating Patients With Stage IV Melanoma</brief_title>
  <official_title>Phase II Trial of Non-Myeloablative Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation Using Fludarabine, Low-Dose TBI, and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil (MMF) Followed by Donor Lymphocyte Infusion in Selected Patients With Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy such as fludarabine use different ways to stop tumor&#xD;
      cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to&#xD;
      damage tumor cells. Peripheral stem cell transplantation may be able to replace immune cells&#xD;
      that were destroyed by chemotherapy or radiation therapy. Sometimes the transplanted cells&#xD;
      can reject the body's normal tissues. Donor lymphocytes that have been treated in the&#xD;
      laboratory may prevent this.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of chemotherapy, total-body irradiation,&#xD;
      peripheral stem cell transplantation, and lymphocyte infusion in treating patients who have&#xD;
      stage IV melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the objective response rate in patients with metastatic melanoma treated with&#xD;
           nonmyeloablative allogeneic peripheral blood stem cell transplantation with fludarabine&#xD;
           and total body irradiation, followed by cyclosporine and mycophenolate mofetil, followed&#xD;
           by donor lymphocyte infusion.&#xD;
&#xD;
        -  Determine the disease-free and overall survival of patients treated with this regimen.&#xD;
&#xD;
        -  Determine the toxicity of this nonmyeloablative conditioning regimen in these patients.&#xD;
&#xD;
      OUTLINE: Patients receive a conditioning regimen comprising fludarabine IV on days -4 to -2&#xD;
      and total body irradiation on day 0. Allogeneic peripheral blood stem cells are infused on&#xD;
      day 0.&#xD;
&#xD;
      Patients receive oral cyclosporine twice a day on days -3 to 35 and tapered until day 56 and&#xD;
      oral mycophenolate mofetil 3 times a day on days 0-40.&#xD;
&#xD;
      Patients with mixed chimerism and no graft-versus-host disease on day 56 receive donor&#xD;
      lymphocyte infusion (DLI) over 30 minutes on day 65 unless there is evidence of increasing&#xD;
      donor chimerism. DLI may be repeated every 65 days for up to 4 doses.&#xD;
&#xD;
      Patients are followed weekly for 3 months, monthly for 6 months, every 6 months through year&#xD;
      2, and then annually through year 5.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 15-30 patients will be accrued for this study within 4 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2000</start_date>
  <completion_date type="Actual">December 2003</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic allogeneic lymphocytes</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed stage IV melanoma&#xD;
&#xD;
          -  Partial response, minor response, or stable disease after no more than 2 regimens of&#xD;
             chemotherapy, immunotherapy, or chemoimmunotherapy&#xD;
&#xD;
          -  Bidimensionally measurable disease by palpation on clinical exam or radiographic&#xD;
             imaging&#xD;
&#xD;
          -  HLA genotypically identical sibling donor available&#xD;
&#xD;
               -  Not an identical twin&#xD;
&#xD;
               -  Age 12 to 74&#xD;
&#xD;
          -  No ocular melanoma&#xD;
&#xD;
          -  No active or untreated brain metastases or transmural gastrointestinal metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 to 64&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 80-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  SGOT and SGPT less than 2 times ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine clearance at least 40 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  LVEF at least 40% if history of congestive heart failure&#xD;
&#xD;
          -  No uncontrolled hypertension&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  DLCO at least 50% of predicted&#xD;
&#xD;
          -  No continuous supplementary oxygen&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 1 year after study&#xD;
             participation&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent growth factors during mycophenolate mofetil administration&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John A. Thompson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Seattle Cancer Care Alliance</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <study_first_submitted>September 11, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>November 28, 2011</last_update_submitted>
  <last_update_submitted_qc>November 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2011</last_update_posted>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

